在初级渐进性失言症中,阿尔茨海默病病理学的认知标志物? 在临床环境中进行验证研究
Valeria Isella1, Daniele Licciardo2, Gaia Rebecchi1
1School of Medicine and Surgery, University of Milano - Bicocca, Monza (MB), Italy.
Neurobiology of aging
|September 2, 2023
概括
一种用于诊断粉样蛋白阳性原发性渐进性失语症 (PPA) 的新临床标志物显示出中度的特异性,但敏感性较低. 数字跨度损伤可能发生在各种PPA亚型中,与左额叶皮层功能有关.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 生物标志物研究 生物标志物研究
背景情况:
- 初级渐进性失言症 (PPA) 的诊断可能具有挑战性.
- 粉样蛋白阳性是某些PPA亚型的关键生物标志物.
- 数字跨度 (DS) 已被提议作为声学循环功能障碍的标记.
研究的目的:
- 在临床环境中验证粉素阳性PPA的临床标志物.
- 为了评估粉样阳性PPA的损伤的数字跨度的诊断准确性.
- 探索PPA中数字跨度和神经退行模式之间的关系.
主要方法:
- 对29名粉胺阳性 (A+) 和28名粉胺阴性 (A-) PPA患者的回顾性分析.
- 接收器运行特性 (ROC) 曲线分析以评估标记器性能.
- 统计参数映射 (SPM) 是DS得分与大脑新陈代谢 (18--脱氧-葡萄糖正子发射断层扫描) 之间的相关性.
主要成果:
- 拟议的标志物对A+ PPA.表现出适度的特异性 (71%),但对A+ PPA.表现出不足的敏感性 (41%).
- 在区分A+ PPA和非流行的A- PPA时,特异性明显较低 (58%).
- 损伤的DS与左额叶皮层的新陈代谢有关,这表明它参与了PPA亚型的声学处理缺陷.
结论:
- 经过验证的临床标记因敏感性不足而对粉样蛋白阳性PPA具有有限的诊断效用.
- 数字跨度损伤并不特定于logopenic PPA,并且可以在非流动的PPA中受到影响.
- 左额叶皮层的完整性对声学处理至关重要,正如DS性能与大脑代谢之间的相关性所示.
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


